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Abstract 
 
Atrial fibrillation (AF) is the most common tachyarrhythmia in the adult population and 
is a major cause of morbidity and mortality. AF can be terminated and sinus rhythm 
restored by prolonging the action potential duration (APD) and the refractory period. 
Unfortunately, antiarrhythmic agents that prolong the APD and increase the refractory 
period via selective inhibition of the rapid delayed rectifier potassium current (IKr), i.e. 
class III antiarrhythmic drugs, are associated with an increased risk of the ventricular 
tachycardia Torsades de Pointes. AZD7009 is an antiarrhythmic agent with predominant 
actions on atrial electrophysiology that shows high antiarrhythmic efficacy and low 
proarrhythmic potential in animals and man. The aim of the current studies was to 
characterize the effect of AZD7009 on cardiac ion currents and APD in order to provide 
a mechanistic explanation for its predominant atrial effects and low proarrhythmic 
potential. 
 
The human cardiac ion channels hERG (IKr), Kv1.5 (IKur), Kv4.3/KChIP2.2 (Ito), 
KvLQT1/minK (IKs), Kir3.1/Kir3.4 (IKACh) and Nav1.5 (INa) were expressed in 
mammalian cells. Whole-cell currents were inhibited by AZD7009 with the following 
IC50 values: hERG 0.6 μM, Nav1.5 8 μM, Kv4.3/KChIP2.2 24 μM, Kv1.5 27 μM, 
Kir3.1/Kir3.4 166 μM and KvLQT1/minK 193 μM. Whole-cell sodium and calcium 
currents were recorded in isolated rabbit atrial and ventricular myocytes using 
amphotericin B perforated patch. The late sodium current in rabbit atrial and ventricular 
myocytes was inhibited by AZD7009 in a concentration dependent way, with 
approximately 50% inhibition at 10 μM AZD7009. The L-type Ca2+ current (ICaL) in 
rabbit ventricular myocytes was inhibited with an IC50 of 90 μM. Transmembrane action 
potentials were recorded in tissue pieces from rabbit atrium, ventricle and Purkinje fibre 
in control, during exposure to the selective IKr blocker E-4031 and to E-4031 in 
combination with AZD7009. In Purkinje fibres, but not in ventricular tissue, AZD7009 
attenuated the E-4031-induced APD prolongation. In contrast, in atrial cells, AZD7009 
further prolonged the APD. In addition, AZD7009 was able to suppress early 
afterdepolarisations (EADs) induced by E-4031 in Purkinje fibre preparations. 
 
In conclusion, AZD7009 delays repolarisation and increases refractoriness in atrial 
tissue through synergistic inhibition of IKr, Ito, IKur and INa, a mixed ion channel 
blockade that may underlie its high antiarrhythmic efficacy. Inhibition of the late sodium 
current, counteracting excessive APD prolongation and EADs in susceptible cells 
(midmyocardial and Purkinje cells), may explain the low proarrhythmic potential of 
AZD7009. 
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